Member Info for Richob

To apply the test needs minimum 97% sensitivity and 99% specificity.

Those numbers ring a bell.

https://support-covid-19-testing.dhsc.gov.uk/5f7212e0d3e36d3fc57bddea/582b176a-8816-4e3a-868e-c333cc1b751e

Onwards Avacta.

Can't see Medusa not completing this.

https://support-covid-19-testing.dhsc.gov.uk/5f7212e0d3e36d3fc57bddea/582b176a-8816-4e3a-868e-c333cc1b751e

Affidx has to be the best available test and you have to credit the Boohoo Boys with sales nous when it comes to these matters.

Roll on Monday.

Onwards Avacta.

https://www.bbc.co.uk/news/health-58921280

Timing is everything.

Onwards Avacta.

Whilst 54k shares may not be a lot in the scheme if things, I would have thought even more staff buying is a positive. Glad I joined them today.

Onwards Avacta.

... is pleased to announce "The Ramper Bus".

This leaves at 7 am tomorrow morning just after the HUA RNS.

To qualify for your free ticket, you need to either:

a) Be on "the ramper list".
b) Always put Strong Buy on your posts.
c) Post anything positive about the company.

Shame on all the rampers, myself included, for being positive about a share they have bought.

Sujood will be driving the bus after he has written the HUA RNS and we are driving out to the country for a nice lunch.

All aboard.

Onwards Avacta.

Willie Walsh has just mentioned "rapid antigen tests" for holidays on the BBC news.

He must have got the phrase from somewhere.

Onwards Avacta.

Unless there is a leak, Timster !

Onwards Avacta.

Interestingly, Timster, the Medusa website says about the Rapid Saliva Test:

"We always aim to have at least 2 million units in stock readily available. Our production line is entirely scalable to meet customer needs."

Seems like they understand how manufacturing capability is key.

Onwards Avacta.

The Medusa "blurb" actually says:

"This Framework Contract allows the provision to all UK Government Departments and Trusts across England, Scotland, Northern Ireland and Wales subject to access agreement signature and Schedule 6 pricing, to supply the Rapid Saliva Protein Test (RSPT) and Avacta’s professional use AffiDx SARS-CoV-2 Antigen Lateral Flow Tests.

The Medusa tests detailed above and other parties lateral flow tests are now available for purchase by various government departments subject to their demand requirements."

I don't see how this can be misinterpreted but can see that Medusa don't yet have sufficient Affidx tests and therefore could well be interested in making them themselves, which would give them additional profit.

There is no doubt that the Medusa owners know how to sell and I can't see why they would invest £20m in a commercial venture if they weren't looking for a substantial return on it.

Onwards Avacta.

The share price has gone down and we see posts about:

Myles McNulty
Alistair Smith
Legal action

Time for some people to grow up.

This small company has:

a) Started one of eight planned cancer trials
b) Is selling a lateral flow test
c) Has numerous agreements with large pharmas

There are various RNSs that could appear:

a) Update on LFT sales
b) Increases manufacturing capacity for the above
c) Update on AVA6000 initial trial
d) An additional cancer trial
e) Confirmation of achieved milestones with various companies

Not sure what anybody is expecting for 115p a share but that will do for me and attacking Alistair Smith and Myles McNulty is pathetic.

Onwards Avacta.

Agent B. I thought the detection of variants, such as Delta, fitted into the "DHSC recognises that it is not possible to predict every possible innovation. If a manufacturer has developed a test with an unforeseen advantage, we reserve the right to review and permit submission for validation if the scientific consensus supports the claim" category?

Onwards Avacta.

Good question, roundhowe but maybe not so simple.

Looks like the sites may specialise in different cancer types could be one part of the rationale.

I also see that Sheffield, as an example, is involved in a number of different trial types.

Personally happy with the confidence shown by the new scientific advisory board members who are more than likely to know how it is going and at what speed. Also think that any announcement of a second site recruiting would confirm more than just that.

All the best.

Onwards Avacta.

.... actually reads better than the RNS.

Excellent appointment on top of various other appointments that Poirot has highlighted.

Onwards Avacta.

I agree that Dr Goldberg isn't risking his career by joining Avacta.

More likely looking for a way to crown it.

What better way than being involved in the cancer treatment that targets the actual tumour rather than other bodily organs.

Excellent appointment.

Onwards Avacta.

The timing of the appointment is very interesting, Wiggly, coming, as it does, just one week after AVA6000 first dosing.

I see that Dr. Goldberg is the past-chair of the Eastern New England Area Board of the American Cancer Society and currently serves as a member of its national board of directors.

IND filing is becoming an improved probability.

Onwards Avacta.

Gruffell,

I think I have been here at least as long as you and nobody is pleased at the falling sp, caused by some holders in a panic (opinion) and a lack of understanding that this causes the drop. It is clear to me that larger buyers are taking advantage and the question is why would they?

Well, compared to where the company was, there is now an LFT on sale and BAMS is also on sale through Adeptrix.

Far more importantly, the company now has AVA6000 in clinical trials. This makes the company a clinical trial oncology company, which is way more than it was.

None of this was true a year ago but the sp has fallen, hence the conundrum.

On most AIM shares, buyers are looking for a quick return. Some will have had that here and gone already. Some only came for the LFT and it didnt come quickly enough for them, not that covid has gone away or that testing due to variants isn't even more important than it was.

Others still believe that we are only at the start of where this will be going rather than at the end.

I am in the latter category and hence hold (and buy when I can).

You will only be "skint" if you sell just at the point where the company is about to move forward.

There are plenty of us in the same boat as you and it is currently needing more people to row in the same direction.

I doubt this helps but I have at least tried. My belief is that we are just at the beginning.

All the best.

Onwards Avacta.

We closed yesterday at 106p with an Uncrossing Trade at 110p, so opened 4p down.

We have closed today at 105p.

Three buys of 100k shares hoovered up today's sells quite easily.

Some larger buyers appear to be taking advantage over (at least) the last few days.

Onwards Avacta.

LG Chem $62billion.

Thought we should have a new thread for those, like me, that are buying at these prices.

Time will tell of course but institutions were happy buying in above this price.

Onwards Avacta.

It has been difficult watching the share price fall over recent weeks is probably something people can agree on.

It is also something that the institutional investors are likely bemused by.

Having invested £55m on the back of Affimer IP and Precision IP, providing sufficient funds for increased Affimer production and the AVA trial and two plus years running costs, it must have come as a surprise that after both the LFT production and sales (albeit volumes unknown) and the commencement of the AVA trial, that the sp is below their entry point.

I wouldn't be surprised if one or more of them decided to buy more as it seems unlikely they would sell at a loss and their reasons for buying in haven't changed (arguably further on) and I also wouldn't be surprised if they have contacted Avacta for some degree of understanding given their initial outlay and commitment.

(I am aware that Conifer reduced their position at a point but there can be numerous reasons for that decision and they still had plenty of shares left at the last count.)

Just a thought and prepared to be shot at but also why I have added some.

All the very best to everybody holding and buying through this period, painful as it has been.

I think the company is further forward now than it has ever been.

Onwards Avacta.